Massive Bio

Massive Bio, founded in 2015, aims to democratize access to cutting-edge cancer treatment by leveraging technology and expert knowledge. The company's core mission is to connect cancer patients with the best possible clinical trials and treatment options, regardless of their location. Massive Bio offers virtual oncology advisory services, including a virtual tumor board that collaborates with treating oncologists to provide expert recommendations. Their market focus is on cancer patients seeking specialized, personalized treatment plans facilitated through advanced data analytics and AI.

Notable affiliated individuals include co-founders Dr. Arturo Loaiza-Bonilla, a prominent oncologist, and Selin Kurnaz, an expert in healthcare technology. The company has attracted significant investment from venture capital firms specializing in healthcare innovation. Key achievements include partnerships with major cancer centers and the development of a robust AI-driven platform that matches patients with clinical trials. Massive Bio's impact is evident in its ability to bridge the gap between patients and cutting-edge treatments, significantly improving patient outcomes and advancing cancer research.